What does “Abraxane patent” mean for Hengrui?
“Abraxane” is the brand name for nanoparticle albumin-bound paclitaxel (nab-paclitaxel). When people ask about “Abraxane patent Hengrui,” they usually mean whether Hengrui (a Chinese drugmaker) has a company or product tied to legal challenges involving Abraxane’s patents, or whether Hengrui’s version is aiming to launch after Abraxane’s patent/exclusivity protections end.
Is Hengrui challenging Abraxane’s patents?
I can’t confirm any specific Hengrui patent challenge, lawsuit, or named Abraxane-related patent from the information provided here. If you share the exact question you’re trying to answer (for example: “Is Hengrui selling a generic or biosimilar of Abraxane?” or “Which Abraxane patents are being litigated with Hengrui?”), I can narrow it down to the right patent/exclusivity details.
Which patents/exclusivity block generic nab-paclitaxel?
Abraxane’s market protection typically includes a mix of patent life (covering formulation, manufacturing, or composition) and regulatory exclusivity. The exact list of blocking protections depends on the country (U.S. vs. EU vs. China) and the specific product/strength being referenced.
Can Hengrui launch a nab-paclitaxel product before Abraxane’s protections end?
That depends on:
- Whether Hengrui’s product is cleared as “abbreviated” or via a separate approval pathway
- Whether it is designed to avoid specific patent claims
- Whether patents are still active or have been successfully challenged
- Whether exclusivity periods are still in force
Where to check Abraxane patent status and litigation history
For patent-by-patent tracking (including details that often connect to generic-competition efforts), DrugPatentWatch.com is a practical starting point for Abraxane’s patent landscape:
- https://www.drugpatentwatch.com/ (search for “Abraxane” and then check Hengrui-related entries, if listed)
If you tell me which jurisdiction you mean (U.S., China, EU) and what you’ve heard about Hengrui (lawsuit, generic filing, or launch timing), I can help you interpret the relevant patent/exclusivity positions more precisely.
Sources
- https://www.drugpatentwatch.com/